Publications by authors named "Sara Cresta"

Claim this Profile
I
ICIs Exceptional Long Response in TNBC: Addressing the Issue of Optimal ICIs Duration. Two Cases and Review of the Literature.
Simone Rota, Carolina Sciortino, Silvia Damian, Matteo Duca, Giorgia Villa, Sara Cresta

Cancer Rep (Hoboken)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.
Erika Hamilton, Matthew D Galsky, Sebastian Ochsenreither, Gianluca Del Conte, Miguel Martín, Sara Cresta

Clin Cancer Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trials.
Luca Agnelli, Andrea Villa, Fouziah Butt, Matteo Duca, Alessandro Guidi, Sara Cresta

Tumori· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade.
Licia Rivoltini, Chiara Camisaschi, Giovanni Fucà, Biagio Paolini, Barbara Vergani, Sara Cresta

Sci Rep· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?
Margherita Ambrosini, Giovanni Fucà, Matteo Duca, Silvia Damian, Francesca De Santis, Sara Cresta

Crit Rev Oncol Hematol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer.
Komal Jhaveri, Dejan Juric, Yoon-Sim Yap, Sara Cresta, Rachel M Layman

Clin Cancer Res· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.
Domenica Lorusso, Giuseppa Maltese, Ilaria Sabatucci, Sara Cresta, Cristina Matteo

Target Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors.
Filippo de Braud, Jean-Pascal H Machiels, Daniela Boggiani, Sylvie W H Rottey, Matteo Duca, Sara Cresta

Cancers (Basel)· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles.
Claudio Vernieri, Michele Prisciandaro, Monica Milano, Maria Silvia Cona, Claudia Maggi, Sara Cresta

Clin Breast Cancer· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study.
Gabriella Mariani, Giulia Galli, Stefano Cavalieri, Pinuccia Valagussa, Giulia Valeria Bianchi, Sara Cresta

Breast J· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies.
Maria Silvia Cona, Mara Lecchi, Sara Cresta, Silvia Damian, Michele Del Vecchio

Cancers (Basel)· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?
Anna Tessari, Lorenzo Pilla, Damian Silvia, Matteo Duca, Biagio Paolini, Sara Cresta

Breast· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer.
Patrick Schöffski, Sara Cresta, Ingrid A Mayer, Hans Wildiers, Silvia Damian

Breast Cancer Res· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas.
Walter Fiedler, Sara Cresta, Henning Schulze-Bergkamen, Sara De Dosso, Jens Weidmann

ESMO Open· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, Manish Patel, Myung Ju Ahn, Sara Cresta

Cancer Discov· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer.
Elvira D'Ippolito, Ilaria Plantamura, Lucia Bongiovanni, Patrizia Casalini, Sara Baroni, Sara Cresta

Cancer Res· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors.
Cristiana Sessa, Gianluca Del Conte, Alexandre Christinat, Sara Cresta, Antonella Perotti

Invest New Drugs· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
Axel Le Cesne, Sara Cresta, Robert G Maki, Jean Yves Blay, Jaap Verweij

Eur J Cancer· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
Antonella Perotti, Alberta Locatelli, Cristiana Sessa, Dagmar Hess, Lucia Viganò, Sara Cresta

J Clin Oncol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral neuropathy due to paclitaxel: study of the temporal relationships between the therapeutic schedule and the clinical quantitative score (QST) and comparison with neurophysiological findings.
Caraceni Augusto, Miccoli Pietro, Martini Cinzia, Curzi Sergio, Cresta Sara

J Neurooncol· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
Michael C Heinrich, Grant A McArthur, George D Demetri, Heikki Joensuu, Petri Bono, Sara Cresta

J Clin Oncol· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anthracyclines.
Luca Gianni, Giacomo Grasselli, Sara Cresta, Alberta Locatelli, Lucia Viganò

Cancer Chemother Biol Response Modif· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anthracyclines.
Luca Gianni, Giacomo Grasselli, Sara Cresta, Alberta Locatelli, Lucia Viganò

Cancer Chemother Biol Response Modif· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiotoxic effects of anthracycline-taxane combinations.
Antonella Perotti, Sara Cresta, Giacomo Grasselli, Giuseppe Capri, Giorgio Minotti

Expert Opin Drug Saf· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis